These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28838287)

  • 1. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Leuk Lymphoma; 2018 May; 59(5):1105-1112. PubMed ID: 28838287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
    Hoffmann VS; Baccarani M; Lindoerfer D; Castagnetti F; Turkina A; Zaritsky A; Hellmann A; Prejzner W; Steegmann JL; Mayer J; Indrak K; Colita A; Rosti G; Pfirrmann M
    Leukemia; 2013 Oct; 27(10):2016-22. PubMed ID: 23752173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
    Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
    Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
    Zhang XS; Gale RP; Huang XJ; Jiang Q
    Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
    Huang J; Wang L; Chen L; Qun H; Yajing X; Fangping C; Xielan Z
    Turk J Haematol; 2017 Mar; 34(1):10-15. PubMed ID: 27751981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
    Jabbour E; Cortes J; Nazha A; O'Brien S; Quintas-Cardama A; Pierce S; Garcia-Manero G; Kantarjian H
    Blood; 2012 May; 119(19):4524-6. PubMed ID: 22431574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
    Kanakasetty GB; Thanky AH; Kuntegowdanahalli L; Dasappa L; Jacob L; Mallekavu SB; Lakkavalli R; Kadabur L; Antapura R
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):375-381. PubMed ID: 28502460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
    Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
    Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia.
    Iriyama N; Hatta Y; Kobayashi S; Uchino Y; Miura K; Kurita D; Kodaira H; Inoue M; Takei M
    Int J Hematol; 2014 Oct; 100(4):379-85. PubMed ID: 25092482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
    Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
    Tiribelli M; Bonifacio M; Calistri E; Binotto G; Maino E; Marin L; Guardalben E; Branca A; Gherlinzoni F; Semenzato G; Sancetta R; Pizzolo G; Fanin R
    Leuk Res; 2013 Nov; 37(11):1457-60. PubMed ID: 23993428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
    Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
    Hu B; Savani BN
    Eur J Haematol; 2014 Sep; 93(3):179-86. PubMed ID: 24766312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
    Nteliopoulos G; Bazeos A; Claudiani S; Gerrard G; Curry E; Szydlo R; Alikian M; Foong HE; Nikolakopoulou Z; Loaiza S; Khorashad JS; Milojkovic D; Perrotti D; Gale RP; Foroni L; Apperley JF
    Haematologica; 2019 Dec; 104(12):2400-2409. PubMed ID: 31073075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
    Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
    Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
    Huang J; Zhao X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 41(8):809-14. PubMed ID: 27600007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.